-
Many of the generic manufacturers started years back with knock off drugs to sell locally in India, but now the game is changing to where US Pharma is using some of the talent, which costs less than R and D individuals here in the states, to further develop existing work, in other words somewhat continue...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
09-05-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Genomics, drugs, Pharma, Biotech, Cancer, FDA, Budgets, R and D, Alzheimers, Outsourcing
-
For those of you who read the blog here and are not aware of what a "Carnival" is, it represents a collection of some of the top blogging posts in a period of time assembled in one place to review and read. Today, Highlight Health is hosting the carnival and I am delighted that...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
09-05-2008
Filed under:
Filed under: Medically Related, Technology, Genomics, healthcare, Proteins, Cancer, cancer research, Pharmacogenomics, R and D, Bloggers, Stand up to Cancer
-
In a related story about the Broad Institute, this was released today: potential news and warnings of tumors that could become resistant to a common cancer drug when used upon a recurrence of a tumor. There's a lot going on with genomic research at the center and this is just one...
-
Genetic markers making their way to electronic medical records with locating potential patients through medical records to perhaps identify candidates that would benefit. Cerner is one of the larger software companies used by many hospitals in the US. A genetic test that would allow identification...
-
I get a kick out of stories like this, although there could be something to it. If the man has RS3 334, then toss him out it appears and the more copies the worse! But let's not leave this little factor just up to the male species, there's females out there too with issues. ...
-
This lends itself to an area whereby various area of cancer could be targeted, and with few or little side effect as the study states. The term "cellular immortality" is the term that describes cells that keep regenerating endlessly, like cancer cells do. It's a long way to...
-
Is Biotech risky business? I think we can all agree due to the research and development and the unknown areas as far as predicting a winner can be close to a roll of the dice at times. The bar has risen a bit today to secure VC funds no doubt and then we still hear about the failed trials...
-
This is an article written by Misha Angrist is an assistant professor at the Duke University Institute for Genome Sciences and discusses what do we do with our genome once we get it? Actually the article talks about where we are today with the technology. The only thing I think that we all...
-
This is hot stuff! Recently I had an in depth interview with Dr. Patrice Milos, Chief Scientific Officer at Helicos discussing genomics and where the future is going. Helicos has the software and the genomics machine, and wouldn't this be a nice addition to run on Surface. This...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
08-27-2008
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, Microsoft/Windows News, Hospital, Genomics, healthcare, microsoft, Surface, Cardiology, Touch Screen, HIMMS, Surface Technology, Helicos, Heart Transplant, MSDN, Scripps, Healthblog
-
Progress is being made and appears both sides are satisfied here. DeCode has also applied for a license. Both companies appear to be using a physician for the test results which was at the crux of the matter. We also need more physicians who understand genomics too, and recently DeCode...
-
The videos are well worth watching as well as fascinating. These are not just "techs" working at the labs, they are physicians, PHDs, etc. that are working on the healthcare items. These are just a few screen shots from the videos. There's all kinds of interesting projects...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
08-18-2008
Filed under:
Filed under: Medically Related, Technology, Microsoft/Windows News, Genomics, healthcare, microsoft, PACS, Radiology, software, DNA Testing, HIV Research, Microsoft Labs
-
It should be the discretion of individual physicians, not insurance companies or pharmacies, to substitute a branded biologic for a biosimilar, which goes back to putting the physician in the decision making process, not the non clinical analyzers. While the search for "cheap" continues...
-
This is indeed one controversial subject. What is potentially behind all of this is that we don't have physicians linked in here. When you stop and give this some thought, who do you want discussing your healthcare with you, your family practice doctor most of us would probably say,...
-
Dentists now are coming in to the fold of DNA genomics tests. This test is very specific to assess risk for periodontal disease, so as a younger patient, as chances are as we age if we are at risk we may already have this, this could be a good indicator for the dentist to have in the knowledge...
-
Part of the success of Amgen was using a smaller amount of individuals for clinical trials, and looking at results during the trial instead of an overall evaluation process at the conclusion. It also helps keep the cost of the clinical trials down by conducting studies for biomarkers, or signature...